| scholarly article | Q13442814 |
| P50 | author | Tore K. Kvien | Q65660760 |
| P2093 | author name string | C Kaufmann | |
| P Mowinckel | |||
| K Mikkelsen | |||
| E Rødevand | |||
| M S Heiberg | |||
| A Didriksen | |||
| P2860 | cites work | Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure | Q81712916 |
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis | Q94174915 | ||
| Adalimumab for treating rheumatoid arthritis | Q24246674 | ||
| Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious | Q24795061 | ||
| A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate | Q28295474 | ||
| Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? | Q33782365 | ||
| Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 | ||
| Clinical outcome measures in rheumatoid arthritis | Q34071257 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 | ||
| Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). | Q34544500 | ||
| Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 | ||
| Evidence supporting the benefit of early intervention in rheumatoid arthritis | Q34999223 | ||
| Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Q35554130 | ||
| Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues | Q35579347 | ||
| Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial | Q35636868 | ||
| New drugs for rheumatoid arthritis | Q35777601 | ||
| Infliximab treatment of rheumatoid arthritis | Q35789078 | ||
| The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups | Q36759493 | ||
| The estimation of a preference-based measure of health from the SF-36. | Q40647897 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire | Q71095022 | ||
| Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes | Q74455180 | ||
| Validation of rheumatoid arthritis improvement criteria that include simplified joint counts | Q77430935 | ||
| The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing | Q78794804 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| multicenter clinical trial | Q6934595 | ||
| adalimumab | Q348260 | ||
| methotrexate | Q422232 | ||
| P304 | page(s) | 1379-1383 | |
| P577 | publication date | 2006-05-05 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study | |
| P478 | volume | 65 |
| Q41106264 | Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. |
| Q36749766 | Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation |
| Q46171462 | Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice |
| Q37873493 | Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
| Q37372556 | Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. |
| Q34413310 | Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont |
| Q58775879 | Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q37804483 | The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review |
| Q64084969 | Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms |
| Q36984088 | Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort |
Search more.